# A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

> **NCT07456046** · PHASE1 · RECRUITING · sponsor: **D3 Bio (Wuxi) Co., Ltd** · enrollment: 42 (estimated)

## Conditions studied

- KRAS P.G12D

## Interventions

- **DRUG:** D3S-003

## Key facts

- **NCT ID:** NCT07456046
- **Lead sponsor:** D3 Bio (Wuxi) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-01-11
- **Final completion:** 2028-01-11
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07456046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07456046, "A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07456046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*